Skip to main content
SpringerLink
Log in

Clinicopathological Nomogram for Predicting Platinum-Resistant/Refractory Epithelial Ovarian Cancer

  • Original Article
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Objective

To construct a nomogram of individual risks from exploratory clinicopathological features associated with platinum-resistant/refractory epithelial ovarian cancer (EOC).

Methods

Patients who were diagnosed with EOC stage IA-IB, grades 2–3, and greater than stage IC, from January 1, 2005, to December 30, 2013, after the debulking of the tumors, were studied retrospectively. Additionally, they had received adjuvant treatment with a paclitaxel-carboplatin regimen at Songklanagarind Hospital. The patients’ data (demographic, surgical, laboratory, pathological results, and clinical outcomes) were collected. The clinicopathological features associated with platinum-refractory/resistant EOC were assessed using univariate and multivariate logistic regression analyses. Significant factors were used to construct a nomogram; the nomogram predictive accuracy was measured via a concordance index (c-index) and validated using the bootstrap validation method.

Results

Of 235 patients included, the prevalence of platinum-resistant/refractory EOC was 19.1% overall and 36.8% for recurrent EOC. The clinicopathological features associated with platinumrefractory/ resistant EOC were parity, size of residual tumor, grade, International Federation of Gynecology and Obstetrics (FIGO) staging, platelet count, and number of cycles of chemotherapy. The nomogram c-index and mean absolute error were 0.83 and 0.03, respectively.

Conclusion

One-fifth of the women with EOC and one-third with recurrent EOC had platinum-refractory/resistant EOC. The clinicopathological features, including parity, size of residual tumor, grade, FIGO staging, platelet count, and number of cycles of chemotherapy, are useful as predictors of platinumrefractory/ resistant EOC. Patients with these significant factors and with a high probability of developing platinum-resistant/refractory EOC should be considered for close surveillance and be made aware of recurrent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. International Agency for Research on Cancer, World Health Organization. Cancer today. Estimated age-standardized incidence and mortality rates (World) in 2020, worldwide, females, all ages; 2020. Retrieved from: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Atrue%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D [accessed 6 Nov 2021]. IARC and WHO

  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer; 2021. Retrieved from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453 [accessed 26 Febr 2021]

  3. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24-32. https://doi.org/10.1093/annonc/mdt333.

    Article  PubMed  Google Scholar 

  4. Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015. https://doi.org/10.1002/14651858.CD004706.pub5.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Rizzuto I, Stavraka C, Chatterjee J, Borley J, Hopkins TG, Gabra H, et al. Risk of ovarian cancer relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int J Gynecol Cancer. 2015;25:416–22. https://doi.org/10.1097/IGC.0000000000000361.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Nguyen TT, Wright JD, Powell MA, Gibb RK, Rader JS, Allsworth JE, et al. Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2008;18:1194–9. https://doi.org/10.1111/j.1525-1438.2007.01184.x.

    Article  CAS  PubMed  Google Scholar 

  7. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85:944–52. https://doi.org/10.1054/bjoc.2001.2030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012;125:25–30. https://doi.org/10.1016/j.ygyno.2011.12.423.

    Article  PubMed  Google Scholar 

  9. Pisano C, Bruni GS, Facchini G, Marchetti C, Pignata S. Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag. 2009;5:421–6. https://doi.org/10.2147/tcrm.s4317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 2002;7(Suppl 5):20–8. https://doi.org/10.1634/theoncologist.7-suppl_5-20.

    Article  CAS  PubMed  Google Scholar 

  11. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–106. https://doi.org/10.1016/s0140-6736(03)13718-x.

    Article  CAS  PubMed  Google Scholar 

  12. Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell’Anna T, et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the Calypso phase III trial. Eur J Cancer. 2015;51:352–8. https://doi.org/10.1016/j.ejca.2014.11.017.

    Article  CAS  PubMed  Google Scholar 

  13. Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG. 2009;116:372–80. https://doi.org/10.1111/j.1471-0528.2008.02033.x.

    Article  CAS  PubMed  Google Scholar 

  14. Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2013;24:937–43. https://doi.org/10.1093/annonc/mds538.

    Article  CAS  PubMed  Google Scholar 

  15. Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer. 2011;105:1144–50. https://doi.org/10.1038/bjc.2011.364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Classe JM, Jaffre I, Frenel JS, Bordes V, Dejode M, Dravet F, et al. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. Eur J Surg Oncol. 2011;37:971–7. https://doi.org/10.1016/j.ejso.2011.08.138.

    Article  CAS  PubMed  Google Scholar 

  17. Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, et al. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pac J Cancer Prev. 2013;14:2421–7. https://doi.org/10.7314/apjcp.2013.14.4.2421.

    Article  PubMed  Google Scholar 

  18. International Agency for Research on Cancer, World Health Organization. CI5 plus Cancer Incidence in five Continents Time Trends. Thailand (4 registries) Age Standardized Incidence Rate (World), Female Age [0–85+]; 2014. Retrieved from: http://ci5.iarc.fr/CI5plus/old/Graph4p.asp?cancer%5B%5D=50&cancer%5B%5D=110&cancer%5B%5D=152&cancer%5B%5D=162&cancer%5B%5D=172&cancer%5B%5D=182&female=2&country%5B%5D=76400000&sYear=1950&eYear=2012&stat=3&age_from=1&age_to=18&orientation=1&window=1&grid=1&line=2&moving=1&scale=0&submit=%C2%A0%C2%A0%C2%A0Execute%C2%A0%C2%A0%C2%A0 [accessed 6 Nov 2021]. IARC and WHO

  19. International Agency for Research on Cancer, World Health Organization. Cancer today. Estimated age-standardized incidence and mortality rates (World) in 2020, ovary, females, all ages; 2020. Retrieved from: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=population&mode_population=countries&population=900&populations=900&key=asr&sex=2&cancer=25&type=0&statistic=5&prevalence=0&population_group=4&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=20&group_cancer=1&include_nmsc=1&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Atrue%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D&population_group_list=4,51,31,48,50,64,96,116,160,275,268,356,360,364,368,376,392,400,398,408,410,414,417,418,422,458,462,496,104,524,512,586,608,634,682,702,144,760,762,764,626,792,795,784,860,704,887&population_group_globocan_id=935 [accessed 6 Nov 2021]. IARC and WHO

  20. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010;195:281–9. https://doi.org/10.2214/AJR.09.4110.

    Article  PubMed  Google Scholar 

  21. Zhang Z, Kattan MW. Drawing nomograms with R: applications to categorical outcome and survival data. Ann Transl Med. 2017;5:211. https://doi.org/10.21037/atm.2017.04.01.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70. https://doi.org/10.1200/JCO.2007.12.9791.

    Article  PubMed  Google Scholar 

  23. Skírnisdóttir I, Sorbe B. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy. Int J Gynecol Cancer. 2007;17:1231–7. https://doi.org/10.1111/j.1525-1438.2007.00928.x.

    Article  PubMed  Google Scholar 

  24. Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;129:63–8. https://doi.org/10.1016/j.ygyno.2013.01.009.

    Article  CAS  PubMed  Google Scholar 

  25. Chi DS, Palayekar MJ, Sonoda Y, Abu-Rustum NR, Awtrey CS, Huh J, et al. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma. Gynecol Oncol. 2008;108:191–4. https://doi.org/10.1016/j.ygyno.2007.09.020.

    Article  PubMed  Google Scholar 

  26. Shafrir AL, Babic A, Tamimi RM, Rosner BA, Tworoger SS, Terry KL. Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. Br J Cancer. 2016;115:1391–9. https://doi.org/10.1038/bjc.2016.316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610–8. https://doi.org/10.1056/NEJMoa1110352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014;124:184–7. https://doi.org/10.1182/blood-2014-03-562538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Allensworth SK, Langstraat CL, Martin JR, Lemens MA, McGree ME, Weaver AL, et al. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol. 2013;130:499–504. https://doi.org/10.1016/j.ygyno.2013.05.038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bottsford-Miller J, Choi HJ, Dalton HJ, Stone RL, Cho MS, Haemmerle M, et al. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015;21:602–10. https://doi.org/10.1158/1078-0432.CCR-14-0870.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research project was supported by a grant (EC 58–210-12–4) from the Faculty of Medicine, Prince of Songkla University. We would like to give sincere thanks to Ms.Nannapat Kaewmunee and Professor Alan Geater for calculating sample sizes and analyzing the data and the Department of International Affairs, for their editing of the grammar in this manuscript.

Funding

The authors are grateful to the Prince of Songkla University for enabling them to conduct the research (EC 58–210-12–4).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand

    Nungrutai Saeaib & Siriwan Chaowanadisai

  2. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand

    Tippawan Liabsuetrakul

Authors
  1. Nungrutai Saeaib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siriwan Chaowanadisai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tippawan Liabsuetrakul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nungrutai Saeaib.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethics approval

This retrospective chart review study, involving human participants, was in accordance with the ethical standards of the institutional and national research committee. In addition with the 1964 Helsinki Declaration: its later amendments or comparable ethical standards. The Ethics Committee of the Faculty of Medicine, Prince of Songkla University (EC 58–210-12–4) approved this study.

Informed consent

The informed consent from the patients was not required because of the study’s retrospective nature.

Animals rights

This research did not involve any animals.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saeaib, N., Chaowanadisai, S. & Liabsuetrakul, T. Clinicopathological Nomogram for Predicting Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Indian J Gynecol Oncolog 22, 60 (2024). https://doi.org/10.1007/s40944-024-00823-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-024-00823-y

Keywords

Search

Navigation